les opportunités dans le domaine de la santé...les opportunités dans le domaine de la santé...

Les opportunités dans le domaine de la santé

Horizon-2020 appels 2018

Les slides seront disponibles sur le site web du NCP-Wallonie

- 2 -

Cross-cutting

activities

- 3 -

Cross-cutting

activities

28/09/2017

Societal Challenge 1

- 4 -

SC1 “Health, demographic change and well-being”

Call 1: Better health care, economic growth and sustainable health systemsCall 2: Digital transformation in Health and CareCall 3: Trusted digital solutions and Cybersecurity in Health and Caree-

heal

th


- 5 -

Horizon-2020 SC1 – Projets avec des Wallons

Towards tailored, needs-driven, safer and cost-effective

management of Crohn’sdisease

A systems medicine approachto chronic inflammatory

diseases

Call 1 – Better health and care, economic growth and sustainable health

Better health and care, economic growth and sustainable health• Contributing to better health and healthy ageing • Developing sustainable health and care systems and growth opportunities for the health and care

related industries• Translating new knowledge into innovative applications and accelerating large-scale uptake and

deployment in different health and care settings • Making health and care systems and services more accessible, responsive and efficient in Europe and

beyond5 main priorities• Personalised medicine• Innovative health and care industry• Infectious diseases and improving global health• Innovative health and care systems – integration of care• Decoding the role of the environment for health and well-being.

- 6 -


- 7 -7

26.07.2018 02.10.2018 16.04.2019 Sept2019

OuvertureappelsDépôtdesprojets

Stage1(10pages)

Résultatdel’évaluation

Signaturecontrat

Structurationidéeetbudget

Identificationpartenaires

Réunionconsortium

Rédaction Évaluation Finalisationducontrat

Exécutiondu

projet

Dépôtdesprojets

Stage2

RédactionÉvaluation

fin2019


- 8 -

SC1-BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities• Identify and validate causative mechanisms (e.g. molecular, genetic, correlative, drug-drug interaction)

combining mental and physical disorders through the integration of basic, pre-clinical and/or clinical research (excluding clinical trials)

• Possibly development of biomarkers and other technologies for diagnosis and monitoring • Use of existing data, biobank, registeries, cohorts and/or generation of new data• Sex & gender, lifestyle, socio-economics, behaviourial factors• Participation of SMEsImpact

New directions for clinical research to improve prevention, diagnosis, prognosis, therapy development, and management of co- and multimorbidities.

: 4-6M€ :02.10.201816.04.2019

: 10-15projetsRIA


- 9 -

SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disordersDevelop new concepts of combinatorial therapies for complex disorders tailored to the needs of individuals or stratified patient groups.• Understand at systems level the pathophysiology of a disorder in groups of patients • Focus on already available and/or authorised therapies• New + existing data : re-analyse with modern high-throughput technologies existing standardized patient

biobank samples ➔ build more sophisticated computational frameworks to predict patient responses to combinatorial therapies. Predictions validated in pre-clinical and clinical studies

• Sex & gender, Participation of SMEsImpact• Improved efficacy and take-up in the clinical setting• Enable the development of personalised medicine• Increased research & innovation opportunities (SMEs)

: 4-6M€ :02.10.201816.04.2019

: 8-12projetsRIA


- 10 -

SC1-BHC-07-2019: Regenerative medicine: from new insights to new applicationsInnovative translational research to develop regenerative processes towards the ultimate clinical goal of addressing unmet clinical needs of large patient groups• New approaches such as genome editing or gene therapy, transdifferentiation or in vivo reprogramming, cell

therapy & transplantation, 3D bioprinting, organoids or use of combined products, … • Research on improved methods of tissue and organ transplantation is included on the condition that there is a

clear regenerative step in the process.• Project may focus on any step(s) on the innovation chain : early testing and characterization of regenerative

mechanisms, preclinical research, proof of concept or clinical trial. • Investigate sex & gender difference• To be included : exploitation potential, regulatory & commercialisation strategy and how it would be made

available and delivered to patients.

: 6-8M€ :16.04.2019 : 6-8projetsRIA


- 11 -

SC1-BHC-10-2019: Innovation Procurement: Next Generation Sequencing (NGS) for routine diagnosisThe introduction of NGS in clinical practice is hampered by its cost, the availability of proper NGS tests, and diagnostic errors resulting from insufficient quality assurance, technological bias and complex interpretation of data• objective is to implement NGS in routine diagnostics for personalised medicine and scale up demand-driven

innovation for healthcare systems. • … including organisational, economical, technical and clinical aspects.• It should lead to NGS tests, clinically validated procedures (including sex analysis), quality assurance schemes,

tools and methods for data collection, management, analysis and interpretation, with a view to assist clinical decision-making and foster medical research and innovation.

• Transferability and cloud based NGS data analyses should be considered, as appropriate. • Ethical issues should be addressed.

: 9-11M€ :16.04.2019 : 4 projetsPCP Pre-Commercial Procurement


- 12 -

SC1-BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factorsFor (re-)emerging infectious disease threats, develop :• the technology to allow : pooling, access, analysis & sharing of data, including next generation sequencing;• the innovative bio-informatics and modelling methodologies that enable risk modelling and mapping; and• the analytical tools for early warning, risk assessment and monitoring

Linking data from a wide range of relevant sources : • human (e.g. community, hospital or laboratory health services), animal health surveillance, health registries, microbial

and viral genomic data - NGS, pathogen resistance data, mapping of vectors, climate and environmental data, as well as societal data

➔ demonstrate the feasibility of such extended data mining at EU level• address the interoperability between different data sources + integration • + data privacy, security, etc, open access in case of emergencies/ public use free or affordable price

: 12-15M€ :16.04.2019 : 2-3projetsRIA


- 13 -

SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseasesTest emerging concepts in drug and/or vaccine development in order to address the problem of antimicrobial drug resistance and to optimize therapeutic, curative or preventive measures • approach based on knowledge of the role of host factors, immune-modulators or of host-pathogen interactions

influencing disease outcome … leading to new enhanced therapies, cures and/or preventive measures. • Projects should• include factors such as age, gender and genetic variation among the human population • focus on late pre-clinical and/or clinical research, supporting proof of concept and selecting relevant biomarkers for

clinical validation.• take advantage of existing or newly established cohorts to help identify factors for predicting the course of the disease

and its response to the intervention in stratified patients.

: 6-10M€ :02.10.201816.04.2019

: 9-16projetsRIA


- 14 -

SC1-BHC-19-2019: Implementation research for maternal and child healthEach year : 140 million newborn babies. However, many of the women and infants receive no appropriate care or below standardsResearch for improving maternal & child health with a focus on first 1000 days from pregnancy until 2 years of age• in either high income countries or low and middle income countries, or in combination• include end-users : the concerned women, the fathers, and their community, in addition policy makers,

politicians, and media, to ensure that evidence can be translated into policy and practice• integrate different perspectives : health promotion and treatment; allowing for the specific needs of vulnerable

groups (e.g. preterm infants, adolescents, migrants); addressing different concurrent pathologies• research may cover :• new or improved health service delivery interventions that strengthen maternal and child health; and/or• the scaling up and/or adapting of existing evidence-based interventions to new contexts. • physical and/or mental health, as well as communicable and non-communicable diseases.

Out of scope : pre-clinical research, clinical trials in the context of product development

: 2-4M€:02.10.201816.04.2019

: 6-12projetsRIA


- 15 -

SC1-BHC-22-2019: Mental health in the workplaceDepression, anxiety and stress ➔ health problems, costs and lost productivityProposals should • develop and implement intervention(s) - new or improvement of existing ones - that an employer/ organization

can take to promote good mental health & prevent mental illness in the workplace. • involve key partners such as employers and employees in the private and public sector, policy makers, insurers,

social partners and civil society in developing initiativesProjects should adress :• existing knowledge or may well go beyond• co-morbidities in mental and/or physical health• multidisciplinary research including social sciences and the humanities, relevant gender issues, ethics • the stigma attached to mental ill health & other social and cultural factors which may be relevant

: 2-4M€ :02.10.201816.04.2019

: 7-15projetsRIA


- 16 -

SC1-BHC-25-2019: Demonstration pilots for implementation of personalised medicine in healthcarePersonalised medicine - PM : Increasing number of scientific approaches available ➔ demonstrate the benefit :

• of large scale deployment to citizens and healthcare systems,• economic viability and mplementability (+ ethical, legal and societal aspects)

• focus on diseases with high burden to society ➔ wider that only cancer and rare diseases• involve and link healthcare actors (hospitals, other healthcare facilities, public health authorities, payers, patient

representatives etc)• coordination with national, regional or local authorities • engage partners in regions or cities having adopted or are advanced in PM approaches • encouraged : use of big data approaches and high performance computing

: 18-20M€ :02.10.201816.04.2019

: 3projetsIA


- 17 -

SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on healthFrom ‘one exposure, one disease’ understanding to a more complex pictureCollect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases• evaluation of the role of multiple and unknown exposures and assessment of individual exposure to multiple

stressors (+ in utero exposure)• integration of external exposome data with cross-omics responses and (epi)genetic data; systematic evaluation and

simulations of the health impacts; • biomarker, bio-informatics development, sensors (incl. new) combining external exposure & health data• better data mining tools, high-performance/high throughput computing and storage; • socio-economic modelling and econometric analysis (if relevant ethical and sex/gender aspects) ➔ A long-term host and a single shared data infrastructure / open access➔ Coordination between funded projects required

: 8-12M€ :16.04.2019 : 4-6projetsRIA


- 18 -

SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on healthFrom ‘one exposure, one disease’ understanding to a more complex pictureCollect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases• evaluation of the role of multiple and unknown exposures and assessment of individual exposure to multiple

stressors (+ in utero exposure)• integration of external exposome data with cross-omics responses and (epi)genetic data; systematic evaluation and

simulations of the health impacts; • biomarker, bio-informatics development, sensors (incl. new) combining external exposure & health data• better data mining tools, high-performance/high throughput computing and storage; • socio-economic modelling and econometric analysis (if relevant ethical and sex/gender aspects) ➔ A long-term host and a single shared data infrastructure / open access➔ Coordination between funded projects required

: 8-12M€ :16.04.2019 : 4-6projetsRIA


- 19 -

SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine

International aspects• Building links with third countries based on advantages of collaboration in PM• Promoting international standards in PM and uptake of PM • 2019: China

Regional aspects• Establish and support networking between regions in EU (between remote and sparsely

populated regions and other regions with critical mass)• Structure PM application at regional level

Healthcare- and pharma-economic models for Personalized Medicine• Support new health- and pharma economic models for PM to develop relevant health financing

models• Analyse mid- and long- term impacts of PM innovative products• Ensure patients access, data safety and financial sustainabilty of public health systems• Based on existing work/initiatives• Dissemination!

- 20 -

: 1,5-2M€ :16.04.2019 :2projetsCSA

28/09/2017 - 21 -

Budget # projetsfinancés Deadline

SC1–BHC-19-2019: Understanding causative mechanisms in co- and multimorbidities RIA 4-6M€ 5 02.10.2018 16.04.2019

SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders RIA 4-6M€ 10 02.10.2018

16.04.2019

SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine• International aspects: China• Standardisation for clinical studies design

CSA 1,5-2M€ 2 16.04.2019

SC1-BHC-07-2019: Regenerative medicine: from new insights to new applications RIA 6-8M€ 6-7 16.04.2019

SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis PCP 9-11M€ 3-4 16.04.2019

SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases RIA 6-10M€ 9-15 02.10.2018

16.04.2019

SC1-BHC-19-2019: Implementation research for maternal and child health RIA 2-4M€ 5-10 02.10.2018 16.04.2019

SC1-HCO-08-2019: Creation of a European wide sustainable clinical research network for infectious diseases CSA 2-3M€ 1 16.04.2019

28/09/2017 - 22 -


SC1-BHC-22-2019: Mental health in the workplace RIA 2-4M€ 7-15 02.10.201816.04.2019

SC1-BHC-25-2019: Demonstration pilots for implementation of personalised medicine in healthcare IA 18-20M€ 3 02.10.2018

16.04.2019

SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health RIA 8-12M€ 4-6 16.04.2019

- 23 -

Cross-cutting

activities

28/09/2017


- 24 -28/09/2017

SC1-NMBP-22-2018: Osteo-articular tissues regeneration

Conceive innovative designs and development of innovative user-centred biomaterials enabling the delivery of smart, nanostructured and functionalised tissues for personalised regeneration of bones, cartilages, tendons and joints. • Smart and innovative nanobiomaterials also adaptable to remote control • Materials will perform in host tissues affected by severe inflammatory processes• Technologies: 3D-bioprinting, Stem cells technologies, nanofunctionalisation, 3D-printable

biophotopolymeration, additive manufacturing, electrospinning, cross-cutting KETs• SSH & user involvement • Cooperation with other projects + accessibility and reusability of data

: 4-6M€ :début2018? :4-6projetsRIA

28/09/2017 - 25 -


NMBP-21-2020: Custom-made biological scaffolds for specific tissue regeneration and repair RIA ? ? ?

DT-NMBP-23-2020: Next generation organ-on-chip (RIA) RIA ? ? ?

A vous de jouer

- 26 -28/09/2017

Passer à l’action

- 27 -28/09/2017

Oser initier des contacts & viser l’excellence

Activer votre réseau

Key-players H2020

Participer à des événements

Proposer des contributions concrètes et spécifiques au topic

Trouver des projets financés / partenaires

- 28 -

https://cordis.europa.eu/projects/home_en.html

28/09/2017 - 29 -

Diffuser son profil

- 30 -

Topic Identifié

Données administratives

Contribution concrète au projet / Valeur ajoutée

Fiche du NCP Wallonie« One-page expertise description »

28/09/2017

Diffuser son profil

28/09/2017

http://mm.fitforhealth.eu/

InfoDay “Health”, 07-08.12.17, Brussels• https://www.b2match.eu/healthBE2017

- 31 -

http://www.healthncp.net/ https://www.imi.europa.eu/content/partner-search /

Recherches partenaires/ diffuser son profil

- 32 -

http://ec.europa.eu/research/participants/portal

Fin

- 33 -

Merci pour votre attention

Pierre Fiasse European Project DeveloperHorizon 2020 Nano, Materials, Transport & Aero NCPTél: +32 (0) [email protected]

Vos contacts au NCP-Wallonie :

Marie Stas (apd 11-06-2019)European Project DeveloperHorizon 2020 Health, Biotechnology, Agriculture & Food NCPTél : +32 (0) 10.48.50.33 [email protected]

les opportunités dans le domaine de la santé...les opportunités dans le domaine de la santé...

Documents